Mismatch in perceptions of the quality of supervision and research data management as an area of concern: Results from a university-wide survey of the research integrity culture at a Belgian university.

Researchers of KU Leuven, a large Belgian university, were invited to complete a bespoke questionnaire assessing their attitudes toward research integrity and the local research culture, with specific emphasis on the supervision of junior researchers. A total of 7,353 invitations were sent via e-mail and 1,866 responses were collected (25.3% response rate), of which 1,723 responses are reported upon here. Some of the findings are relevant to the broader research community. Whereas supervisors evaluated their supervision of junior researchers almost unanimously as positive, fewer supervisees evaluated it as such. Data management emerged as an area of concern, both in terms of reviewing raw data and of data storage. More female than male professors emphasized open communication and supported their supervisees' professional development and personal well-being. At the same time, fewer female professors felt safe to speak up than male professors. Finally, researchers who obtained their master's degree outside Europe evaluated their supervision and KU Leuven's research culture more positively than researchers with a master's degree from KU Leuven. The results of the survey were fed back to the university's board and several bodies and served as input to update the university's research policy. Faculties and departments received a detailed report.

Addressing the needs of people with extensively drug-resistant TB through pre-approval access to drugs and research.

Multiple therapeutic options exist for people with drug-resistant TB (DR-TB), but there is an urgent need to improve access to novel compounds and regimens for people with difficult to treat forms of TB. In additional to formal research studies and clinical trials, other mechanisms of accessing promising new TB compounds need to be introduced as soon as these drugs have shown efficacy and safety in phase II trials. Pre-approval access programs for newer TB drugs such as bedaquiline, delamanid, and pretomanid all suffered from shortcomings. These can be addressed for the next generation of new TB drugs through a series of concerted actions by stakeholders at multiple levels. In this viewpoint, we advocate for transparent, accessible pre-approval access as a core element of person-centered care for DR-TB.

Il existe de nombreuses options thérapeutiques pour les personnes atteintes de TB résistante aux médicaments (DR-TB), mais il est urgent d'améliorer l'accès aux nouvelles molécules et aux nouveaux schémas thérapeutiques pour les personnes atteintes de formes de TB difficiles à traiter. Outre les études de recherche formelles et les essais cliniques, d'autres mécanismes d'accès aux nouvelles molécules prometteuses contre la TB doivent être mis en place dès que ces médicaments ont démontré leur efficacité et leur innocuité lors des essais de phase II. Les programmes d'accès avant approbation pour les nouveaux médicaments contre la TB tels que la bédaquiline, le delamanid et le pretomanid ont tous souffert de lacunes. Ces problèmes peuvent être résolus pour la prochaine génération de nouveaux médicaments contre la TB grâce à une série d'actions concertées entre les parties prenantes à différents niveaux. Dans cette optique, nous préconisons un accès transparent et accessible avant approbation, en tant qu'élément central des soins centrés sur la personne pour la DR-TB.